Per Odin

List of Publications by Year
in descending order

86 papers	6,984 citations	109321 35 h-index	60623 81 g-index
88 all docs	88 docs citations	88 times ranked	4703 citing authors

#	Article	IF	Citations
1	Caregiver Burden in Late-Stage Parkinsonism and Its Associations. Journal of Geriatric Psychiatry and Neurology, 2022, 35, 110-120.	2.3	18
2	Diagnostic work up: Laboratory and biomarkers. International Review of Neurobiology, 2022, 162, 53-96.	2.0	0
3	Does the 5â€“2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5â€“2-1-positive patients in 7 countries. BMC Neurology, 2022, 22, 35.	1.8	12
4	Caregiver Burden and Quality of Life in Late Stage Parkinsonâ€™s Disease. Brain Sciences, 2022, 12, 111.	2.3	13
5	Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinsonâ€™s disease. Scientific Reports, 2022, 12, 526.	3.3	18
6	Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinsonâ€™s Disease: Real-World Evidence From G7 Countries. Neurology and Therapy, 2022, 11, 303-318.	3.2	6
7	Safinamide in the treatment pathway of Parkinsonâ€™s Disease: a European Delphi Consensus. Npj Parkinson's Disease, 2022, 8, 17.	5.3	7
8	Quality of life and resource utilizationâ€Swedish data from the Care of Lateâ€Stage Parkinsonism (CLaSP) study. Acta Neurologica Scandinavica, 2022, 145, 743-752.	2.1	4
9	Opicapone versus placebo in the treatment of Parkinsonâ€™s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone) Tj ETQq1 1 0.784314 rgBT /Ov		
10	Validation of the PD home diary for assessment of motor fluctuations in advanced Parkinsonâ€™s disease. Npj Parkinson's Disease, 2022, 8, .	5.3	9
11	Characteristics of Patients with Late-Stage Parkinsonism Who are Nursing Home Residents Compared with those Living at Home. Journal of the American Medical Directors Association, 2021, 22, 440-445.e2.	2.5	18
12	Longitudinal prediction of falls and near falls frequencies in Parkinsonâ€™s disease: a prospective cohort study. Journal of Neurology, 2021, 268, 997-1005.	3.6	6
13	The Nonâ€Motor Symptoms Scale in Parkinsonâ€™s disease: Validation and use. Acta Neurologica Scandinavica, 2021, 143, 3-12.	2.1	49
14	Perspectives on Care for Late-Stage Parkinsonâ€™s Disease. Parkinson's Disease, 2021, 2021, 1-11.	1.1	13
15	Factors Associated with Healthâ€Related Quality of Life in Lateâ€Stage Parkinson's Disease. Movement Disorders Clinical Practice, 2021, 8, 563-570.	1.5	16
16	Swedish guidelines for deviceâ€aided therapies in Parkinson's disease â€”Economic evaluation and implementation. Acta Neurologica Scandinavica, 2021, 144, 170-178.	2.1	7
17	Cost-Effectiveness of Device-Aided Therapies in Parkinsonâ€™s Disease: A Structured Review. Journal of Parkinson's Disease, 2021, 11, 475-489.	2.8	11
18	Parkinson's Disease and <scp>Postâ€“COVID</scp>â€19 Syndrome: The Parkinson's <scp>Longâ€COVID</scp> Spectrum. Movement Disorders, 2021, 36, 1287-1289.	3.9	51

#	Article	IF	Citations
19	Close relationships in ParkinsonÂ´s disease patients with deviceâ€aided therapy. Brain and Behavior, 2021, 11, e02102.	2.2	5
20	The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on â€˜Offâ€™-time in Patients with Advanced Parkinsonâ€™s Disease: A Systematic Review. Advances in Therapy, 2021, 38, 2854-2890.	2.9	41
21	Parkinsonâ€™s disease in Swedenâ€”resource use and costs by severity. Acta Neurologica Scandinavica, 2021, 144, 592-599.	2.1	11
22	Patient Utilities in Health States Based on Hoehn and Yahr and Off-Time in Parkinsonâ€™s Disease: A Swedish Register-Based Study in 1823 Observations. Pharmacoeconomics, 2021, 39, 1141-1149.	3.3	1
23	Digital health technology for non-motor symptoms in people with Parkinson's disease: Futile or future?. Parkinsonism and Related Disorders, 2021, 89, 186-194.	2.2	26
24	Personalised Advanced Therapies in Parkinsonâ€™s Disease: The Role of Non-Motor Symptoms Profile. Journal of Personalized Medicine, 2021, 11, 773.	2.5	20
25	Advance Care Planning and Care Coordination for People With Parkinson's Disease and Their Family Caregiversâ€”Study Protocol for a Multicentre, Randomized Controlled Trial. Frontiers in Neurology, 2021, 12, 673893.	2.4	7
26	Effects of safinamide on pain in patients with fluctuating Parkinson's disease. Brain and Behavior, 2021, 11, e2336.	2.2	18
27	Gastrointestinal dysfunction in Parkinson's disease. International Review of Movement Disorders, 2021, 1, 179-208.	0.1	0
28	Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications. Parkinsonism and Related Disorders, 2021, 92, 59-66.	2.2	23
29	Clinical Usefulness of Retropulsion Tests in Persons with Mild to Moderate Parkinsonâ€™s Disease. International Journal of Environmental Research and Public Health, 2021, 18, 12325.	2.6	1
30	Everyday Occupations and Other Factors in Relation to Mental Well-Being among Persons with Advanced Parkinsonâ€™s Disease. Occupational Therapy in Health Care, 2020, 34, 1-18.	0.3	0
31	Lack of Accredited Clinical Training in Movement Disorders in Europe, Egypt, and Tunisia. Journal of Parkinson's Disease, 2020, 10, 1833-1843.	2.8	3
32	Levodopa infusion in Parkinson's disease: Individual quality of life. Acta Neurologica Scandinavica, 2020, 142, 248-254.	2.1	4
33	Optimizing Treatment in Undertreated Late-Stage Parkinsonism: A Pragmatic Randomized Trial. Journal of Parkinson's Disease, 2020, 10, 1171-1184.	2.8	6
34	The Prevalence and Determinants of Neuropsychiatric Symptoms in <scp>Lateâ€Stage</scp> Parkinsonism. Movement Disorders Clinical Practice, 2020, 7, 531-542.	1.5	24
35	A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia. Movement Disorders, 2020, 35, 1046-1054.	3.9	12
36	Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The <scp>COVID</scp>â€19 Experience. Movement Disorders Clinical Practice, 2020, 7, 361-372.	1.5	91

#	Article	IF	Citations
37	The late stage of Parkinson's â€“results of a large multinational study on motor and non-motor complications. Parkinsonism and Related Disorders, 2020, 75, 91-96.	2.2	25
38	Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study. Parkinsonism and Related Disorders, 2019, 66, 158-165.	2.2	12
39	Satisfaction with Care in Late Stage Parkinsonâ€™s Disease. Parkinson's Disease, 2019, 2019, 1-10.	1.1	8
40	EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease. Movement Disorders, 2019, 34, 353-365.	3.9	126
41	Disease stage dependency of motor and non-motor fluctuations in Parkinsonâ€™s disease. Journal of Neural Transmission, 2019, 126, 841-851.	2.8	9
42	Levodopa Effect and Motor Function in Late Stage Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2018, 8, 59-70.	2.8	28
43	Mobility device use in people with Parkinson's disease: A 3-year follow-up study. Acta Neurologica Scandinavica, 2018, 138, 70-77.	2.1	14
44	Workforce participation and activities in Parkinson's disease patients receiving device-aided therapy. Acta Neurologica Scandinavica, 2018, 138, 78-84.	2.1	5
45	Study protocol: Care of Late-Stage Parkinsonism (CLaSP): a longitudinal cohort study. BMC Neurology, 2018, 18, 185.	1.8	27
46	Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2018, 8, S65-S72.	2.8	32
47	Dopaminergic Effect on Non-Motor Symptoms in Late Stage Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2018, 8, 409-420.	2.8	18
48	Workforce unavailability in Parkinson's disease. Acta Neurologica Scandinavica, 2017, 135, 332-338.	2.1	10
49	Algorithms for the treatment of motor problems in Parkinson's disease. Acta Neurologica Scandinavica, 2017, 136, 378-385.	2.1	43
50	Factors Contributing to Perceived Walking Difficulties in People with Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2017, 7, 397-407.	2.8	27
51	Device-Aided Treatment Strategies in Advanced Parkinson's Disease. International Review of Neurobiology, 2017, 132, 453-474.	2.0	29
52	Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. Parkinsonism and Related Disorders, 2017, 45, 13-20.	2.2	149
53	Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?. ENeurologicalSci, 2017, 8, 44-53.	1.3	10
54	Infusional Therapies, Continuous Dopaminergic Stimulation, and Nonmotor Symptoms. International Review of Neurobiology, 2017, 134, 1019-1044.	2.0	6

#	Article	IF	Citations
55	Factors associated with life satisfaction in Parkinson's disease. Acta Neurologica Scandinavica, 2017, 136, 64-71.	2.1	38
56	A Consensus Set of Outcomes for Parkinsonâ€™s Disease from the International Consortium for Health Outcomes Measurement. Journal of Parkinson's Disease, 2017, 7, 533-543.	2.8	45
57	Nonâ€oral Continuous Drug Delivery Techniques in Parkinson's Disease: For Whom, When, and How?. Movement Disorders Clinical Practice, 2016, 3, 221-229.	1.5	10
58	Non-oral dopaminergic therapies for Parkinsonâ€™s disease: current treatments and the future. Npj Parkinson's Disease, 2016, 2, 16023.	5.3	43
59	Continuous dopaminergic stimulation therapy for Parkinson's disease â€“ recent advances. Current Opinion in Neurology, 2016, 29, 474-479.	3.6	13
60	Levodopaâ€“Carbidopa Intestinal Gel in Patients with Parkinsonâ€™s Disease: A Systematic Review. CNS Drugs, 2016, 30, 381-404.	5.9	81
61	Integrated safety of levodopaâ€carbidopa intestinal gel from prospective clinical trials. Movement Disorders, 2016, 31, 538-546.	3.9	91
62	Authorsâ€™ Reply to Lambarth: â€œLevodopa-Carbidopa Intestinal Gel in Patients with Parkinsonâ€™s Disease: A Systematic Reviewâ€. CNS Drugs, 2016, 30, 1009-1010.	5.9	1
63	Euro<scp>I</scp>nf: <scp>A</scp><scp>M</scp>ulticenter <scp>C</scp>omparative <scp>O</scp>bservational <scp>S</scp>tudy of <scp>A</scp>pomorphine and <scp>L</scp>evodopa <scp>I</scp>nfusion in <scp>P</scp>arkinson's <scp>D</scp>isease. Movement Disorders, 2015, 30, 510-516.	3.9	203
64	Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. Parkinsonism and Related Disorders, 2015, 21, 1133-1144.	2.2	156
65	The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: A simple grading system. Parkinsonism and Related Disorders, 2015, 21, 287-291.	2.2	93
66	The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study. Neurobiology of Aging, 2015, 36, 1736-1742.	3.1	42
67	Levodopaâ€carbidopa intestinal gel in advanced Parkinson's disease: Final 12â€month, openâ€label results. Movement Disorders, 2015, 30, 500-509.	3.9	199
68	Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinsonâ€™s disease in the UK and Germany. Journal of Medical Economics, 2015, 18, 155-165.	2.1	37
69	Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurology, The, 2014, 13, 141-149.	10.2	547
70	Selecting deep brain stimulation or infusion therapies in advanced Parkinsonâ€™s disease: an evidence-based review. Journal of Neurology, 2013, 260, 2701-2714.	3.6	128
71	Effect and safety of duodenal levodopa infusion in advanced Parkinsonâ€™s disease: a retrospective multicenter outcome assessment in patient routine care. Journal of Neural Transmission, 2013, 120, 1553-1558.	2.8	59
72	Summary of the recommendations of the <scp>EFNS</scp>/<scp>MDS</scp>â€<scp>ES</scp> review on therapeutic management of <scp>P</scp>arkinson's disease. European Journal of Neurology, 2013, 20, 5-15.	3.3	290

#	Article	IF	Citations
73	Levodopaâ€“carbidopa intestinal gel in advanced Parkinson's disease open-label study: Interim results. Parkinsonism and Related Disorders, 2013, 19, 339-345.	2.2	95
74	Nonmotor fluctuations in Parkinson disease. Neurology, 2013, 80, 800-809.	1.1	284
75	A Proposal for a Comprehensive Grading of Parkinson's Disease Severity Combining Motor and Non-Motor Assessments: Meeting an Unmet Need. PLoS ONE, 2013, 8, e57221.	2.5	95
76	Intrajejunal Levodopa Versus Conventional Therapy in Parkinson Disease. Clinical Neuropharmacology, 2012, 35, 205-207.	0.7	51
77	Gender-related differences in the burden of non-motor symptoms in Parkinsonâ€™s disease. Journal of Neurology, 2012, 259, 1639-1647.	3.6	211
78	Chronic Subcutaneous Infusion Therapy with Apomorphine in Advanced Parkinson's Disease Compared to Conventional Therapy: A Real Life Study of Non Motor Effect. Journal of Parkinson's Disease, 2011, 1, 197-203.	2.8	107
79	The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: An international study using the nonmotor symptoms questionnaire. Movement Disorders, 2010, 25, 704-709.	3.9	342
80	Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life. Movement Disorders, 2009, 24, 1468-1474.	3.9	233
81	Continuous Jejunal Levodopa Infusion in Patients With Advanced Parkinson Disease. Clinical Neuropharmacology, 2008, 31, 151-166.	0.7	105
82	The metric properties of a novel nonâ€motor symptoms scale for Parkinson's disease: Results from an international pilot study. Movement Disorders, 2007, 22, 1901-1911.	3.9	838
83	Continuous Intra-intestinal Infusion of Levodopa/Carbidopa in Advanced Parkinson's Disease. European Neurological Review, 2007, , 45.	0.5	4
84	International multicenter pilot study of the first comprehensive selfâ€completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study. Movement Disorders, 2006, 21, 916-923.	3.9	865
85	Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 65, 709-716.	1.9	166
86	Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Annals of Neurology, 1997, 42, 95-107.	5.3	331